0305E299

Candidate's Seat No :_____

B.Sc. (Sem.-IV) Examination

CC 205

Health Hygiene May-2017

Time: 3 Hours

[Max. Marks: 70

Que-1 Answer the following (Any two)

14

- A. Discuss the phases I to IV of Clinical trials.
- B. Write a note on planning and designing of clinical study.
- C. Explain PK/PD Modeling.
- D. Describe Biomarker and its types.

Que-2 Answer the following (Any two)

14

- A. Describe structure and content of a typical clinical study report.
- B. Explain the tools and software used in conducting Clinical trials.
- C. Describe study population and sample size on data analysis in clinical report.
- D. Discuss the importance of publication bias in clinical study report.

Que-3 Answer the following (Any two)

14

- A. Discuss the role of IND in clinical research.
- B. Explain social and political issues related to clinical study.
- C. Describe the role and importance of agencies in drug approval process.
- D. Write a short note on current regulatory requirements in clinical research.

Que-4 Answer the following (Any two)

14

- A. What is Hypercholesterolemia? Discuss a case study on drug CRD5.
- B. Report model for clinical study made on treating acne using Finasteride drug.
- C. Discuss importance and finding of case study on Anti-mullerian drug on hormonal secretion.
- D. Discuss the criteria to be measured for Pre-clinical trials.

Que-5 Answer the following (All are compulsory)

14

- 1. Write the full form of NDA.
- 2. Name any two agencies for drug approval in India.
- 3. What is the use of SPSS in clinical analysis?
- 4. Define Bioequivalence.
- 5. Give difference between Pharmacokinetic and Pharmacodynamic.
- 6. What is Belmont report?
- 7. What are double blinding techniques?
- 8. Why Human clinical studies are widespread in developing countries?
- 9. What do you mean by Placebo?
- 10. Give full form of CIOMS and WMA.
- 11. Write the importance of Baseline in clinical report.
- 12. Enlist the components of clinical report.
- 13. What is bioavailability in clinical research?
- 14. Name the parties having conflicting interest in clinical studies.